Emcure Pharma lists at 31% premium; should you buy, sell or hold the stock?
Emcure Pharmaceuticals listing today: According to analysts, Emcure Pharma is quoting at a reasonable valuation with a niche opportunity to invest in the gynaecology & HIV antivirals therapeutic areas